Hays says current genetic testing gives oncologists a wide variety of information that may make choosing the correct treatment "a little more difficult." Hays adds that within the current treatment paradigm of gynecologic cancer, oncologists are mainly focusing on BRCA mutations.
John Hays, MD, assistant professor, Internal Medicine, College of Medicine, Ohio State University, discusses the plethora of genetic mutation information oncologists have when it comes to treating gynecologic cancers. Hays says current genetic testing gives oncologists a wide variety of information that may make choosing the correct treatment "a little more difficult." Hays adds that within the current treatment paradigm of gynecologic cancer, oncologists are mainly focusing on BRCA mutations.
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
July 22nd 2024An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More